Document Detail


The second window of preconditioning (SWOP) where are we now?
MedLine Citation:
PMID:  20496105     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A standard ischemic preconditioning (IPC) stimulus of one or more brief episodes of non-lethal myocardial ischemia and reperfusion elicits a bi-phasic pattern of cardioprotection. The first phase manifests almost immediately following the IPC stimulus and lasts for 1-2 h, after which its effect disappears (termed classical or early IPC). The second phase of cardioprotection appears 12-24 h later and lasts for 48-72 h (termed the Second Window of Protection [SWOP] or delayed or late IPC). The cardioprotection conferred by delayed IPC is robust and ubiquitous but is not as powerful as early IPC. Although there are some similarities in the mechanisms underlying early and delayed IPC, one of the major distinctions between the two is the latter's requirement for de novo protein synthesis of distal mediators such as iNOS and COX-2 which mediate the cardioprotection 24 h after the IPC stimulus. The phenomenon of delayed IPC has been demonstrated in man using a variety of experimental models. However, its clinical application has been limited by the same factors which affect early IPC- i.e. the need to intervene before the onset of myocardial ischemia, thereby restricting its potential clinical utility to planned settings of acute myocardial ischemia-reperfusion injury such as coronary artery bypass graft surgery, cardiac transplantation and percutaneous coronary intervention. In this article, the focus will be on the origins of delayed IPC, the mechanisms underlying its delayed cardioprotective effect, and the potential areas for its clinical application.
Authors:
Derek J Hausenloy; Derek M Yellon
Related Documents :
9476575 - An atp-sensitive potassium (katp) channel opener, nicorandil, lowers the threshold for ...
15854085 - Effects of ischemic preconditioning in human heart.
15261765 - Release of choline in the isolated heart, an indicator of ischemic phospholipid degrada...
9205165 - Intravenous phenylephrine preconditioning of cardiac grafts from non-heart-beating donors.
4030145 - Left ventricular diastolic filling in patients with left ventricular dysfunction.
2963135 - Myosin content and myosin isoenzyme distribution in the heterotopic rat heart allograft.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  24     ISSN:  1573-7241     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-09-02     Completed Date:  2010-12-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  235-54     Citation Subset:  IM    
Affiliation:
The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiovascular Diseases / etiology,  prevention & control*
Cyclooxygenase 2 / metabolism
Humans
Ischemic Preconditioning, Myocardial / methods*
Myocardial Reperfusion Injury / complications,  physiopathology*
Nitric Oxide Synthase Type II / metabolism
Time Factors
Chemical
Reg. No./Substance:
EC 1.14.13.39/Nitric Oxide Synthase Type II; EC 1.14.99.1/Cyclooxygenase 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  omega-Helices in Proteins.
Next Document:  Impact of freezing/thawing technique on sperm DNA integrity in HIV-1 patients.